The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

A luxury industry has grown around helping wealthy drug addicts kick their habit, but patients say recovery takes more than ...

TxGNN is the first AI model specifically developed to identify drug candidates for rare diseases and conditions with no ...

Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...

With the medical device industry keen to capitalise on the engagement of the video games industry, Medical Device Network ...

In the world of biotechnology, few stories resonate as strongly as that of Pasithea Therapeutics Corp. (NASDAQ: KTTA). On Thursday, the stock saw an impressive surge of +80.31%, reaching $6.90 during ...

Old newspaper boxes are being repurposed into containers that distribute Narcan, an emergency treatment to reverse drug ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...

A Montgomery County, Pennsylvania patient will be one of the country's first patients to receive a newly FDA-approved ...